XML 27 R14.htm IDEA: XBRL DOCUMENT
v3.7.0.1

9. Series B Convertible Preferred Stock Warrants | 6 Months Ended
--- | ---
Mar. 31, 2017
Warrants and Rights Note Disclosure [Abstract] |
Series B Convertible Preferred Stock Warrants | The Company issued several notes in prior periods and converted them resulting in the issuance of warrants. The following table summarizes information about the Company’s warrants at March 31, 2017:
|  | Number of units - Series B Convertible preferred warrants |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (in years) |  |  | Intrinsic Value |
Outstanding at September 30, 2016 |  |  | 118,029 |  |  | $ | 20.80 |  |  |  | 1.73 |  |  | $ | 4,307,493 |
Granted |  |  | – |  |  |  |  |  |  |  |  |  |  |  |  |
Exercised |  |  | – |  |  |  |  |  |  |  |  |  |  |  |  |
Outstanding at March 31, 2017 |  |  | 118,029 |  |  | $ | 20.80 |  |  |  | 1.23 |  |  | $ | 6,927,741 |
Exercisable at March 31, 2017 |  |  | 118,029 |  |  | $ | 20.80 |  |  |  | 1.23 |  |  | $ | 6,927,741 |
Most of the above warrants were issued in connection with the conversion of convertible notes from Isaac Capital Group. When the debts were converted and warrants were issued; the Company determined the fair value of the warrants using the Black-Scholes-Merton model and took a charge to interest expense at the date of issuance. On December 27, 2016, ICG and the Company agreed to amend and exchange the common stock warrants for warrants of series B convertible preferred shares, and the number of warrants held adjusted by an exchange ratio of 5:1 common shares for series B convertible shares. ICG, the holder of the warrants outstanding, is not permitted to sell, transfer, assign, hypothecate, pledge, margin, hedge, trade or otherwise obtain or attempt to obtain any economic value from the series B convertible preferred shares should the warrants be exercised prior to December 31, 2021. All warrant related information presented in these condensed consolidated financial statements and accompanying footnotes has been retroactively adjusted to reflect the conversion of all common stock warrants outstanding to series B convertible preferred share warrants resulting in this action. The exercise price for the warrants outstanding and exercisable into series B convertible preferred shares at March 31, 2017 is as follows:
Series B Convertible Preferred |
Outstanding |  |  | Exercisable |
Number of |  |  | Exercise |  |  | Number of |  |  | Exercise |
Warrants |  |  | Price |  |  | Warrants |  |  | Price |
| 54,396 |  |  | $ | 16.60 |  |  |  | 54,396 |  |  | $ | 16.60 |
| 17,857 |  |  |  | 16.80 |  |  |  | 17,857 |  |  |  | 16.80 |
| 12,383 |  |  |  | 24.30 |  |  |  | 12,383 |  |  |  | 24.30 |
| 33,393 |  |  |  | 28.50 |  |  |  | 33,393 |  |  |  | 28.50 |
| 118,029 |  |  |  |  |  |  |  | 118,029 |  |  |  |  |

X
- Definition The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -URI http://asc.fasb.org/topic&trid=2229140 + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_WarrantsAndRightsNoteDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration